The Kowalinski group at EMBL Grenoble discovered notable differences between the nuclear cap-binding complex in trypanosomes and humans, a critical component in cellular RNA metabolism. Trypanosomes ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

The FDA has granted fast track designation to DYNE-101, a therapy for myotonic dystrophy type 1 (DM1) now in testing in a ...

Late-onset Alzheimer's disease is a debilitating, progressive neurodegenerative disease that affects about 7 million ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with projections pointing to antimicrobial ...

A new study from the Kowalinski group at EMBL Grenoble characterized the structure of an important trypanosomal protein ...

Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 -WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, ...

Studies of living participants and postmortem brains confirm that gene expansion is a promising target for HD prevention ...

DYNE-101 eased myotonia and led to other functional improvements for people with myotonic dystrophy type 1 (DM1) in a ...

This manuscript describes the identification and characterization of 12 specific phosphomimetic mutations in the recombinant full-length human tau protein that trigger tau to form fibrils. This ...